RAPAFLO 4 MG
SILODOSIN : 4 MG · DIN 02361663 · ALLERGAN INC
Health Canada status: CANCELLED POST MARKET
What is RAPAFLO?
RAPAFLO 4 MG contains SILODOSIN : 4 MG. It is listed in the Health Canada Drug Product Database under DIN 02361663, held by ALLERGAN INC, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 06-Dec-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is RAPAFLO used for?
Treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02361663 |
|---|---|
| Brand name | RAPAFLO |
| Generic / active ingredient | SILODOSIN : 4 MG |
| Manufacturer | ALLERGAN INC |
| Strength | 4 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | G04CA04 SILODOSIN |
| AHFS class | 12:16.04.12 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 06-Dec-2021 |
| Original market date | 2011-10-26 00:00:00 |
How is it administered?
8 mg once daily with a meal. For moderate renal impairment (CCr 30-50 mL/min), reduce to 4 mg once daily with a meal. Capsules may be opened and sprinkled on applesauce.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text (section 11 referenced but content not shown).
How is it supplied?
Not explicitly detailed in the provided text (section 12 referenced but content not fully shown).
Contraindications
Hypersensitivity to silodosin; severe hepatic impairment (Child-Pugh ≥ 10); severe renal impairment (CCr < 30 mL/min); concomitant potent CYP3A4 inhibitors; concomitant alpha-blockers.
Warnings and precautions
Orthostatic hypotension and syncope may occur. Rule out prostatic carcinoma before therapy. Intraoperative Floppy Iris Syndrome (IFIS) reported during cataract surgery.
What can be used instead?
Other Canadian products sharing ATC code G04CA04 SILODOSIN. 8 of 13 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-SILODOSIN | 4 MG | CAPSULE | AURO PHARMA INC | MARKETED | DIN 02478501 |
| AURO-SILODOSIN | 8 MG | CAPSULE | AURO PHARMA INC | MARKETED | DIN 02478528 |
| JAMP SILODOSIN | 4 MG | CAPSULE | JAMP PHARMA CORPORATION | MARKETED | DIN 02539519 |
| JAMP SILODOSIN | 8 MG | CAPSULE | JAMP PHARMA CORPORATION | MARKETED | DIN 02539527 |
| PMS-SILODOSIN | 4 MG | CAPSULE | PHARMASCIENCE INC | MARKETED | DIN 02517779 |
| PMS-SILODOSIN | 8 MG | CAPSULE | PHARMASCIENCE INC | MARKETED | DIN 02517787 |
| SANDOZ SILODOSIN | 4 MG | CAPSULE | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02475421 |
| SANDOZ SILODOSIN | 8 MG | CAPSULE | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02475448 |
| AG-SILODOSIN | 4 MG | CAPSULE | ANGITA PHARMA INC. | APPROVED | DIN 02541327 |
| AG-SILODOSIN | 8 MG | CAPSULE | ANGITA PHARMA INC. | APPROVED | DIN 02541335 |
Who else supplies SILODOSIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. SILODOSIN appears in 29 registered pack listings across 7 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.